20186278

Source:http://linkedlifedata.com/resource/pubmed/id/20186278

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0019693, umls-concept:C0021756, umls-concept:C0205267, umls-concept:C1280500, umls-concept:C1963724, umls-concept:C2603343
pubmed:issue	2
pubmed:dateCreated	2010-2-26
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00110812
pubmed:abstractText	The Study of Aldesleukin with and without antiretroviral therapy (STALWART) evaluated whether intermittent interleukin-2 (IL-2) alone or with antiretroviral therapy (ART) around IL-2 cycles increased CD4(+) counts compared to no therapy.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/U01 AI068641
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-10068580, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-10229227, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-10371571, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-10397541, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-10823761, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-10826900, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-10889591, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-10891871, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-11052597, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-11101062, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-11873071, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-15206062, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-16025158, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-17135583, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-19106428, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-19508157, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-7646637, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-8857018, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-9086130, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-9144289, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-9360926, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-9516219, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-9806026, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-9848347, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-9863864, http://linkedlifedata.com/resource/pubmed/commentcorrection/20186278-9952385
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101285081
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents, http://linkedlifedata.com/resource/pubmed/chemical/Carbamates, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2, http://linkedlifedata.com/resource/pubmed/chemical/Lopinavir, http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides, http://linkedlifedata.com/resource/pubmed/chemical/Phosphoric Acid Esters, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidinones, http://linkedlifedata.com/resource/pubmed/chemical/Ritonavir, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/atazanavir, http://linkedlifedata.com/resource/pubmed/chemical/fosamprenavir
pubmed:status	MEDLINE
pubmed:issn	1932-6203
pubmed:author	pubmed-author:BabikerAbdelA, pubmed-author:FoxLawrenceL, pubmed-author:GeyDanielaD, pubmed-author:INSIGHT STALWART Study Group, pubmed-author:LopardoGustavoG, pubmed-author:MarkowitzNormanN, pubmed-author:PatonNicholasN, pubmed-author:TavelJorge AJA, pubmed-author:WentworthDeborahD, pubmed-author:WymanNicoleN
pubmed:issnType	Electronic
pubmed:volume	5
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	e9334
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:20186278-Adult, pubmed-meshheading:20186278-Anti-HIV Agents, pubmed-meshheading:20186278-CD4 Lymphocyte Count, pubmed-meshheading:20186278-Carbamates, pubmed-meshheading:20186278-Drug Administration Schedule, pubmed-meshheading:20186278-Drug Therapy, Combination, pubmed-meshheading:20186278-Female, pubmed-meshheading:20186278-Fever, pubmed-meshheading:20186278-HIV Infections, pubmed-meshheading:20186278-Humans, pubmed-meshheading:20186278-Interleukin-2, pubmed-meshheading:20186278-Lopinavir, pubmed-meshheading:20186278-Male, pubmed-meshheading:20186278-Nausea, pubmed-meshheading:20186278-Oligopeptides, pubmed-meshheading:20186278-Opportunistic Infections, pubmed-meshheading:20186278-Phosphoric Acid Esters, pubmed-meshheading:20186278-Pyridines, pubmed-meshheading:20186278-Pyrimidinones, pubmed-meshheading:20186278-Ritonavir, pubmed-meshheading:20186278-Sulfonamides, pubmed-meshheading:20186278-Treatment Outcome
pubmed:year	2010
pubmed:articleTitle	Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
pubmed:affiliation	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II

More...